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The emergence of one of the most recently described carbapenemases, namely, the New Delhi metallo-lactamase (NDM-1),
constitutes a critical and growingly important medical issue. This resistance trait compromises the efficacy of almost all lactams
(except aztreonam), including the last resort carbapenems.Therapeutical optionsmay remain limitedmostly to colistin, tigecycline,
and fosfomycin. The main known reservoir of NDM producers is the Indian subcontinent whereas a secondary reservoir seems
to have established the Balkans regions and the Middle East. Although the spread of 𝑏𝑙𝑎NDM-like genes (several variants) is
derived mostly by conjugative plasmids in Enterobacteriaceae, this carbapenemase has also been identified in P. aeruginosa and
Acinetobacter spp.Acinetobacter sp.may play a pivotal role for spreading 𝑏𝑙𝑎NDM genes for its natural reservoir to Enterobacteriaceae.
Rapid diagnostic techniques (Carba NP test) and screening of carriers are the cornerstone to try to contain this outbreak which
threatens the efficacy of the modern medicine.
1. Introduction
During the last decade the emergence of carbapenemase-
producing strains among Enterobacteriaceae, Pseudomonas
spp., and Acinetobacter baumannii is remarkable. A variety
of carbapenemases have been reported such as the Ambler
class A KPC-type (mostly identified in Enterobacteriaceae
and Pseudomonas aeruginosa) and GES-type (mostly in A.
baumannii), the Ambler class B metallo-𝛽-lactamases (MBL)
of VIM-, IMP-, GIM-, and NDM-types, and the Ambler class
D carbapenemases of the OXA-48 type in Enterobacteriaceae
and of OXA-23, OXA-24/-40, OXA-58, and OXA-143 types
in Acinetobacter spp. The emergence of the most recently
described carbapenemase, namely, the New Delhi metallo-
𝛽-lactamase (NDM-1), constitutes a critical medical issue.
Indeed, this enzyme compromises the efficacy of almost
all 𝛽-lactams (except aztreonam), including the last resort
carbapenems. Although most of the NDM-producing strains
identified are Enterobacteriaceae, this carbapenemase has
also been reported from Acinetobacter spp. and more rarely
from P. aeruginosa, both species causing severe nosocomial
infections, including urinary tract infections, peritonitis, sep-
ticemia, and pulmonary infections.The Indian subcontinent,
the Balkans regions, and theMiddle East are considered to be
the main reservoirs of NDM producers. Since therapeutical
options are limited to very few antibiotics such as col-
istin, tigecycline, and fosfomycin, hospital- and community-
acquired infections caused by NDM-1 producers are difficult
to eradicate. Isolation of infected patients and carriers and
rapid diagnostic techniques are the key factors that contribute
to contain this outbreak that threatens the efficacy of the
modern medicine.
2. Clinical Impact of the Antibiotic
Resistance Patterns of NDM Producers for
the Treatment
Currently, one of the most clinically significant carbapene-
mase is the recently described NDM-1 (New Delhi metallo-
𝛽-lactamase). This carbapenemase belongs to the class B of
Ambler 𝛽-lactamases classification that includes the metallo-
𝛽-lactamases (MBLs). NDM-1 shares very little identity with
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Figure 1: Antibiogram of a NDM-1-producing K. pneumoniae isolate. The 𝑏𝑙𝑎NDM-1 gene was located onto a IncHIIB plasmid of ca.
∼200 kb in that strain that also harbored two additional 𝛽-lactamase genes (𝑏𝑙𝑎CTX-M-15, 𝑏𝑙𝑎SHV-12, 𝑏𝑙𝑎OXA-1) and an aminoglycoside methylase
(armA) responsible for high-level resistance to all aminoglycosides. PTZ, piperacillin + tazobactam; PIP, piperacillin; TIC, ticarcillin; AMX,
amoxicillin; ETP, ertapenem; TCC, ticarcillin + clavulanic acid; CAZ, ceftazidime; CF, cefalotin; FOX, cefoxitin; IMP, imipenem; AMC,
amoxicillin + clavulanic acid; CTX, cefotaxime; CMX, cefuroxime; MEM, meropenem; ATM, aztreonam; FEP, cefepime; FT, nitrofurantoin;
NOR, norfloxacin; OFX, ofloxacin; CIP, ciprofloxacin; FOS, fosfomycin; TGC, tigecycline; TE, tetracycline; CS, colistin; SSS, sulfonamide;
SXT, sulfamethoxazole + trimethoprim; C, chloramphenicol; NET, netilmicin; GM, gentamicin; AN, amikacin; TM, tobramycin; RA,
rifampicin.
other MBLs, the most similar being VIM-1/VIM-2 with only
32.4% amino acid identity. Compared to VIM-2, NDM-1
displays tighter binding tomost cephalosporins, in particular
to cefuroxime (𝐾mNDM-1 = 8 𝜇M, 𝐾mVIM-2 = 22 𝜇M),
cefotaxime (𝐾mNDM-1 = 10 𝜇M, 𝐾mVIM-2 = 32 𝜇M),
cephalothin (𝐾mNDM-1 = 10 𝜇M, 𝐾mVIM-2 = 44 𝜇M), and
penicillins (𝐾mNDM-1 = 16 𝜇M, 𝐾mVIM-2 = 49 𝜇M). Like all
other MBLs, NDM-1 efficiently hydrolyses a broad range
of 𝛽-lactams including penicillins, cephalosporins, and
carbapenems, just sparing monobactams such as aztreonam.
NDM-1 does not bind to carbapenems as tightly as IMP-1 or
VIM-2 does, and the turnover rate of carbapenem hydrolysis
is similar to that of VIM-2 (𝑘cat/𝐾m are 0.21, 1.2, and
0.99 s−1 ⋅ 𝜇M−1 for NDM-1, IMP-1, and VIM-2, resp.). Similar
to the other MBLs, the active site of NDM-1 contains two
metal ion binding sites: the His and Cys sites. Accordingly, a
3D-structure modelling of the NDM-1 enzyme showed that
two zinc ions were present at both the His and Cys sites with
a distance of 4.20 A˚ [1]. Indeed, the hydrolysis activity of
MBLs depends on the interaction of the 𝛽-lactam molecule
with Zn2+ ion(s) in their active site. Consequently, their
activity is inhibited by chelators of divalent cations, such as
EDTA. Accordingly, the efficacy of EDTA (Ca-EDTA) has
been evaluated in a mouse model of sepsis caused by an
NDM-1-producing Escherichia coli. It has been shown that
a combination therapy using imipenem/cilastatin sodium
(IPM/CS) and Ca-EDTA reduced the bacterial inoculum,
as compared to IPM/CS alone suggesting the possibility to
use Ca-EDTA in clinical therapeutics [2]. Comparison of
IMP-1, VIM-2, and NDM-1 by an in silico approach revealed
that NDM-1 might have greater drug profile and catalytic
efficiency than IMP-1 and VIM-2 due to a larger pocket
opening and a lower distance between the Zn-I ion and
𝛽-lactam oxygen of the carbapenem [3].
It is noteworthy that a quite systematic association
with other antibiotic resistance determinants is observed
in almost all NDM producers (Enterobacteriaceae, Acine-
tobacter, and Pseudomonas). Those associated resistance
determinants are AmpC cephalosporinases, clavulanic acid
inhibited expanded-spectrum 𝛽-lactamases (ESBLs), other
types of carbapenemases (OXA-48-, VIM-, and KPC-types),
and resistance to aminoglycosides (16S RNA methylases), to
quinolones (Qnr), to macrolides (esterases), to rifampicin
(rifampicin-modifying enzymes), to chloramphenicol, and to
sulfamethoxazole [4–9]. Consequently, most of the NDM-1
producers remain susceptible only to two bactericidal antibi-
otics (colistin and fosfomycin) and a single bacteriostatic
antibiotic (tigecycline) [10, 11] (Figure 1). In vitro synergy
combination assays performed with NDM-1 producers with
those three antibiotic molecules showed a synergistic activity
of colistin and fosfomycin, of colistin and tigecycline in rare
cases, whereas most of the antibiotic associations remain
neutral for most of the tested isolates [12]. Since NDM-1 does
not hydrolyze aztreonam, a combination therapy including
aztreonamand avibactam (also namedNXL-104), a novel ser-
ine𝛽-lactamase inhibitor inhibiting themost frequent broad-
spectrum hydrolyzing-𝛽-lactamases hydrolyzing aztreonam
has been suggested as a possible strategy against NDM-1-
producing Enterobacteriaceae.This therapeutic option seems
to be a very efficient combination therapy in vitro [13, 14].
3. Infections Caused by NDM Producers
Since NDM producers were mainly described in Enter-
obacteriaceae, infections caused by NDM producers include
urinary tract infections, peritonitis, septicemia, pulmonary
infections, soft tissue infections, and device-associated infec-
tions. As observed for other multidrug-resistant bacteria,
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it is highly probable that colonization of the gut flora
might precede the infection by NDM producers and orofecal
transmission in the community might occur mostly through
hand contamination, food, and water. Among the NDM-
1-producing Enterobacteriaceae, Klebsiella pneumoniae and
E. coli are the most often described species. Both hospital-
and community-acquired infections have been reported.
However, this carbapenemase is also frequently described
in other enterobacterial species including Klebsiella oxytoca,
Enterobacter cloacae, Citrobacter freundii, Proteus mirabilis,
Salmonella spp., and Providencia spp. Although most of
NDM-producing bacteria are Enterobacteriaceae, this car-
bapenemase was also reported from Acinetobacter spp. [15–
32] and in rare cases Pseudomonas aeruginosa [33, 34].
Since, no specific virulence factor is known to be asso-
ciated with 𝑏𝑙𝑎NDM-1-carrying plasmids [6, 35–39], there
is no evidence that NDM-producing bacteria are more
virulent than other strains [40–42]. However, some rare
isolates of NDM-1-producing virulent enteric bacteria such
as Salmonella [43–45] and Vibrio cholerae [46, 47] have been
described.
4. Epidemiology of NDM-Producing Bacteria
NDM-1 was first identified in 2008 in aK. pneumoniae isolate
recovered from a Swedish patient who has been previously
hospitalized in New Delhi, India [48]. Since then, NDM
carbapenemases are the focus of worldwide attention due to
the rapid dissemination of the corresponding gene among
Enterobacteriaceae and Acinetobacter spp. mainly (Figure 2).
Rapidly, a link between NDM-producing Enterobacteriaceae
and the Indian subcontinent has been pointed out [49–51],
and prevalence rates of NDM-producing Enterobacteriaceae
were found to range from 5 to 18.5% in Indian and Pakistan
hospitals [52–55]. In addition, the 𝑏𝑙𝑎NDM-1 gene was detected
not only in patient samples, but also in drinking water and
seepage samples in NewDelhi [47].The occurrence of NDM-
1-producing bacteria in environmental samples in New Delhi
is significant for people living in the city who often rely
onto public water and poor sanitation facilities. A secondary
reservoir of NDM-1 producers was then highlighted through
several studies reporting patients colonized or infected with
NDM-1 producers originating from the Balkan states [50, 56–
61]. Recent reports also suggested that the Middle East might
be an additional reservoir of NDM producers [62–67]. This
dissemination of NDM producers in the Middle East could
mostly be linked to the population exchange between the
Middle East and the Indian subcontinent. However, NDM-1
producing bacteria have now been reported worldwide with
a rapid dissemination from the two previously described
reservoirs, namely, the Indian subcontinent and the Balkan
countries.
As observedwith the dissemination ofNDM-1-producing
Enterobacteriaceae, NDM-producing Acinetobacter has also
been recovered from environmental samples in China [31].
Currently, the majority of NDM-producing Acinetobacter
spp. are reported from China [18, 19, 25, 29–32] and Middle
East [17, 20–24, 26].
5. Genetic Features of the 𝑏𝑙𝑎NDM Genes
In Enterobacteriaceae, the 𝑏𝑙𝑎NDM-1 gene is located mostly
onto conjugative plasmids belonging to several incompat-
ibility groups [6, 7, 25, 35, 37, 38, 63, 68]. However,
investigation of a worldwide collectionof NDM-1-producing
enterobacterial isolates showed that the current spread of
the 𝑏𝑙𝑎NDM-1 gene is not related to the spread of specific
clones, specific plasmids, or single genetic structure [7]. In
Acinetobacter spp. the 𝑏𝑙𝑎NDM-type genes are found to be
either plasmid- or chromosome-located, and in the rare
NDM-1-producing P. aeruginosa, the 𝑏𝑙𝑎NDM-1 gene was
found to be chromosomally located [33, 34]. Investigations on
the immediate genetic environment of 𝑏𝑙𝑎NDM genes revealed
the presence of a conserved structure that always associated
the complete or truncated insertion sequence ISAba125 at
the 5󸀠-end and the 𝑏𝑙𝑒MBL gene (encoding resistance to the
anticancer drug bleomycin) at the 3󸀠-end of the 𝑏𝑙𝑎NDM genes
[69] (Figure 3). In addition, in several studies focusing on
NDM-producing A. baumannii, the 𝑏𝑙𝑎NDM gene was located
between two copies of the ISAba125 element, forming a
composite transposon named Tn125 [15–17, 20, 24, 26, 70, 71]
(Figure 3). Systematic identification of a truncated form of
this composite transposon in Enterobacteriaceae, while it
was described in its entire form in A. baumannii, strongly
suggesting that Acinetobacter spp. has been a reservoir of
those 𝑏𝑙𝑎NDM genes before targeting enterobacterial species.
Those findings highlight that even though A. baumannii is
usually recognized as a final acceptor for resistance genes, it
may acquire several resistance determinants and then transfer
them to Enterobacteriaceae and Pseudomonas spp.
6. NDM Variants
Since the first description of NDM-1, eight variants of this
enzyme have been published (NDM-1 to -8) (Figure 4) and
ten have been assigned (http://www.lahey.org). The first
variant NDM-2 is a point mutation variant having a C to
G substitution at position 82 resulting in an amino acid
substitution of a proline to an alanine residue at position
28 (Pro → Ala) (Figure 4) [26]. Considering that this point
mutation was located at the last amino acid of the peptide
leader of the enzyme, MIC values of 𝛽-lactams including car-
bapenems showed no significant difference between NDM-1
andNDM-2 producers. NDM-2 has been identified in several
A. baumannii strains [20–22, 26] but not yet in Enterobac-
teriaceae. The NDM-3 variant was described from an E. coli
isolate and differs fromNDM-1 by a single nucleotide change
conferring a peptide sequence change at position 95 (Asp
→ Asn) that does not modify the hydrolytic activities of
the enzyme (Figure 4) [11]. The NDM-4 variant differs from
NDM-1 by a single amino acid substitution at position 154
(Met → Leu) (Figure 4). Kinetic data showed that this amino
acid substitution is responsible for an increased hydrolytic
activity ofNDM-4 compared toNDM-1 toward cefalotin, cef-
tazidime, cefotaxime, imipenem, and meropenem, whereas
cefepimewas less hydrolyzed [72].TheNDM-5 variant shares
the substitution at positions 154 (Met → Leu) with NDM-4,
conferring enhanced hydrolytic activity against carbapenems
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Figure 2: Geographical distribution of NDM producers.
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Figure 3: Schematic representation of 𝑏𝑙𝑎NDM-associated genetic structures identified among Gram-negative clinical isolates. (a) Structure
found in A. baumannii, where the 𝑏𝑙𝑎NDM gene is part of the composite transposon Tn125. (b) Structures found in Enterobacteriaceae and
P. aeruginosa where ISAba125 is presented as full or truncated element with 𝑏𝑙𝑒MBL gene (bleomycin resistance encoding gene) also being
present as full or truncated gene. Genes and their corresponding transcription orientations are represented by horizontal arrows. oriIS of
ISCR21 is indicated by a circle. The 𝑏𝑙𝑎NDM promoter is indicated (P). IS, insertion sequence; gene names are abbreviated according to their
corresponding proteins: 𝑏𝑙𝑒MBL, bleomycin resistance gene; Δiso for truncated phosphoribosylanthranilate isomerase; Δpac for truncated
phospholipid acetyltransferase.
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Figure 4: Alignment of the amino acid sequences of the eight reported NDM variants. Conserved residues of the active site of metallo-
𝛽-lactamases are highlighted in gray. The bolded leucine in position 154 has been described to be responsible to an increased carbapenem
hydrolysis.
and harbors a second amino acid substitution at position
88 (Val → Leu) (Figure 4) [73]. The NDM-6 variant differs
from NDM-1 by a single amino acid substitution at position
233 (Ala → Val) leading to no obvious modification in the
hydrolytic activity of the enzyme (Figure 4) [74]. The NDM-
7 variant was concomitantly described from an E. coli isolate
recovered from a French patient who had travelled to Burma
[75] and an E. coli isolate recovered from a Yemeni patient
previously hospitalized at the Frankfurt University Hospital
in Germany [76]. The 𝑏𝑙𝑎NDM-7 gene differs from 𝑏𝑙𝑎NDM-1 by
two amino-acid substitutions at positions 388 (G→A) and
460 (A→C) corresponding to amino acid substitutions at
position 130 (Asp → Asn) and 154 (Met → Leu), respectively
(Figure 4). The amino acid substitution at position 154 (Met
→ Leu) increases the hydrolysis activity of the enzyme [75,
76]. The amino acid sequence of the last published NDM
variant, namely, NDM-8, has substitutions at positions 130
(Asp → Gly) and 154 (Met → Leu) compared with NDM-1
(Figure 4) [77]. This NDM variant possesses the amino acid
substitution at position 154 (Met → Leu), but its critical
impact on 𝛽-lactams hydrolysis has not been detailed.
7. Identification of NDM Producers
Detection of carbapenemase producers, including NDM
producers, in clinical specimens is based currently on a
preliminary analysis of susceptibility testing results. The US
guidelines (CLSI) (updated in 2013) retained as breakpoints
for Enterobacteriaceae susceptibility (𝑆) ≤ 1 and resistance
(𝑅) > 4mg/L for imipenem and meropenem and 𝑆 ≤ 0.5
and 𝑅 > 2mg/L for ertapenem. The European guidelines
(EUCAST) (updated in 2013) are slightly different and pro-
pose breakpoints for imipenem and meropenem as follows:
susceptible (𝑆) ≤ 2 and resistant (𝑅) > 8mg/L and for
ertapenem 𝑆 ≤ 0.5 and 𝑅 > 1mg/L. Although some
discrepancies might exist for several isolates depending on
the reference used to interpret the antibiogram,MIC values of
ertapenem are often higher than those of other carbapenems
with NDM producers. Consequently, ertapenem would be
the best molecule for suspecting most of the carbapene-
mase producers, including NDM producers, and constitutes
good screening criteria. Notably, this greater sensitivity of
ertapenem compared to the other carbapenems is coun-
terbalanced by its lower specificity. Of note, susceptibility
to carbapenems is observed for some NDM producers and
additional tests for carbapenemase detection are needed to
detect them accurately.
7.1. Detection of a Carbapenemase Activity. One of the com-
monly used techniques is the modified Hodge test (MHT),
which has been used for years. Unfortunately, the MHT has
been proved to lack sensitivity (50%) for detecting NDM-
1 producers. Of note, ZnSO
4
(100 𝜇g/mL) supplementation
in the culture medium significantly increases the sensitivity
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to 85.7% [78]. However, this test has a low specificity with
Enterobacter spp. often overexpressing their chromosomal
cephalosporinase [79]. In addition, results of the MHT are
obtained at least 72 h after the bacterial identification.
UV spectrophotometry analysis of carbapenem hydrol-
ysis has been developed to detect carbapenem hydrolysis.
This method is based on the detection of the decrease
of imipenem absorbance with crude extracts of bacterial
enzymes. Crude extracts can be obtained from an overnight
culture of the tested strain after mechanical lysis. This UV
spectrophotometry-based technique is cheap and has a 100%
sensitivity and a 98.5% specificity for detecting carbapen-
emase activity [80]. However, it is time-consuming and
requires trained microbiologists and expensive equipment.
Analysis of carbapenem hydrolysis by using the MALDI-
TOF technology has been shown to be a useful technique to
detect carbapenemase production in a few hours. This tech-
nique was based on detection of a carbapenem (imipenem,
meropenem, or ertapenem) spectrum and of its main deriva-
tives resulting from carbapenemhydrolysis. After 3 to 4 hours
of incubation of the tested isolate with a carbapenem, the
bacteria were pelleted by centrifugation and the supernatant
containing the carbapenem and its metabolites was tested
by MALDI-TOF mass spectrophotometry. Disappearance
of the peak corresponding to the native carbapenem and
appearance of peak(s) corresponding to the metabolite(s)
resulting on the carbapenemhydrolysis sign a carbapenemase
activity [81–85]. This test has excellent sensitivity and speci-
ficity. However, it again requires trained microbiologists and
expensive equipment.
Themost promising technique is the rapid Carba NP test.
It is based on the detection of the hydrolysis of imipenem
by a color change of a pH indicator (Figure 5). This test
is 100% sensitive and 100% specific for the detection of
any type of carbapemenase produced by Enterobacteriaceae
including NDM producers [86–88]. The Carba NP test has
been also validated for the detection of most carbapenemase-
producing Pseudomonas spp., including all NDM producers
[89]. A second version of the Carba NP test (the Carba NP
test II) has been developed to rapidly differentiate between
the diverse carbapenemase types found in Enterobacteriaceae
and P. aeruginosa. This Carba NP test II combines the
inhibition properties of EDTA with the high efficiency of the
Carba NP test for identification of any type ofMBL producer,
including all NDM producers [90]. Recently, the Carba NP
test has been evaluated to detect carbapenemase-producing
Enterobacteriaceae (𝑛 = 193) directly from spiked blood
cultures. The proposed strategy allows detection of all NDM
producers (𝑛 = 33) in less than 5 hours, with sensitivity and
specificity of 100%, respectively [91]. This test has excellent
sensitivity and specificity. However, it requires homemade
reagents that are not yet commercially available.
7.2. Phenotypic Detection of Metallo-𝛽-Lactamase (MBL) Pro-
ducing Isolates. Detection methods based on the inhibitory
properties of several divalent ions chelators (e.g., EDTA
and dipicolinic acid) may identify MBL producers. A disk-
diffusion test based on the detection of a synergy between a
carbapenem-containing disk (imipenem ormeropenem) and
a disk containing an MBL inhibitor (EDTA or mercaptopro-
pionic acid or dipicolinic acid) has been proposed [92].
A combined disk technique using a carbapenem disk
and the same carbapenem disk supplemented with EDTA
(10 𝜇L of a 0.1M solution at pH 8) has been also proposed
[93]. Using this test, a 5mm increase of the inhibition
diameter around the disk containing imipenem plus EDTA
compared to imipenem alone likely indicates the production
of a MBL. However, those two phenotypic methods are time-
consuming and false-negative results often arise, in particular
when low level of resistance is observed [93].
Among those phenotypic methods, the Etest MBL strip, a
two-sided strip containing gradients of imipenem alone on
one side and imipenem supplemented with EDTA on the
other side, is also commonly used for the detection of MBL
producers. Using this test, at least three doubling dilutions of
theMIC in the presence of EDTA are considered as a positive
result [94].However, severalNDM-producing isolates exhibit
lowMIC of carbapenems, leading to not interpretable results
using the Etest MBL strip.
7.3. Molecular Detection of NDM Producers. All the previ-
ous techniques can detect the carbapenemase production
and, in some cases more precisely, production of an MBL,
but none of them is able to specifically identify an NDM
enzyme or its corresponding gene. Therefore a number of
genotypic approaches have been reported, based on PCR
techniques, including real-time PCR methods able to detect
𝑏𝑙𝑎NDM-positive isolates directly from clinical samples [95,
96]. Those methods, however, have the disadvantage to
be unable to identify any novel carbapenemase gene and
are quite expensive. Commercial DNA microarray methods
are marketed and increase the convenience of those tests
[97]. Although they cannot overcome general limitations
of genotypic techniques those DNA microarrays are able
to identify the presence of carbapenemase and the main
extended-spectrum 𝛽-lactamase and acquired cephalospori-
nases genes. Accordingly, this technique is more adapted for
an epidemiological purpose in order to control an outbreak.
Finally, molecular amplification of the 𝑏𝑙𝑎NDM gene followed
by sequencing is needed to identify the exact nature of the
NDM variant.
8. Detection of Infected and
Colonized Patients
Since the prevention of dissemination of carbapenemase
producers partially relies on an early and accurate detection
of carriers, recommendations for the screening of colonized
patients have been introduced in several countries. Com-
monly, “at-risk” patients, meaning those being colonized
with carbapenemase producers, are patients transferred from
a foreign hospital and those hospitalized in intensive-care
units, in transplantation units, and immunocompromised
patients.
Since the intestinal flora is the main reservoir of Enter-
obacteriaceae, rectal swabs and stools are the most suitable
clinical samples for performing this screening. These spec-
imens may be plated on screening medium, either directly
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Figure 5: Principle (a) and interpretation (b) of the Carba NP test recently developed for the rapid identification of carbapenemase producers
among Enterobacteriaceae and Pseudomonas spp.
or after an enrichment step in broth containing imipenem
0.5–1𝜇g/mL or ertapenem 0.5 𝜇g/mL [98, 99]. In outbreak
situations, this enrichment step might increase the sensitivity
of the screening and consequently reduce the number of
potential false-negative results by increasing the inoculum
of the targeted strain. On the opposite, its disadvantage is
the induced delay (12–24 h) needed to confirm or reject
carbapenemase detection. Although the efficiency of this
enrichment step has not been evaluated for NDM producers,
it has already been shown to improve the detection of KPC
producers.
Regardless of the enrichment step, the specimens have to
be plated on selectivemedia. For that purpose, several screen-
ingmedia have been evaluated and compared to the screening
of carriers of NDMproducers. One of the first testedmedium
was the ChromID ESBL culture medium (bioMe´rieux) con-
taining cefpodoxime used as a selector and which is routinely
used to screen ESBL producers. Since NDM enzymes have
a broad-spectrum activity, they hydrolyze not only car-
bapenems but also expanded-spectrum cephalosporins very
efficiently. Therefore, detection of NDM-producing isolates
using ChromID ESBL (aimed do detect ESBL producers)
is possible but with a low specificity since the selective
agent is a cephalosporin and not a specific carbapenemase
substrate (e.g., a carbapenem). Several media supplemented
with a carbapenemhave been developed andmarketed for the
screening of carbapenemase producers. The first screening
medium targeting KPC producers was the CHROMagar
KPCmedium that containsmeropenem (CHROMagar, Paris,
France) [100]. Using thismedium, carbapenem-resistant bac-
teria are well detected when they exhibit relatively high-level
resistance to carbapenems. Its main disadvantage remains in
its lack of sensitivity, since it does not detect carbapenemase
producers with low-level carbapenem resistance. Indeed,
although NDM producers have often high level resistance
to carbapenems, several isolates that exhibited MICs com-
prised between 0.5 and 1 𝜇g/mL, making their detection
difficult on screening media containing high concentration
of carbapenems [78, 93, 101]. Colorex KPC (E&O labora-
tories, Bonnybridge, UK), another screening medium for
carbapenemase producers, also contains meropenem. Since
the content of this medium is reported to be identical to
that of CHROMagar KPC, only NDM producers with high-
level resistance to carbapenems may be detected, leading to
an accurate detection of 57% to 64% of NDM-producing
Enterobacteriaceae using this medium [55, 102]. A third
commercially available screening medium also contains a
carbapenem (CRE Brilliance, Thermo Fisher Scientific, UK).
Depending on the study, sensitivities for detection of patients
colonized with NDM producers were reported to be 63%
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to 85% using this medium [102, 103]. Another screening
medium also containing a carbapenem is the ChromID
CARBA (bioMe´rieux, La Balmes-les-Grottes, France). This
commercially available medium has been reported to be
more sensitive (87.5% to 94%) than the others for the
detection of NDM-producing Enterobacteriaceae [55, 102,
103]. Finally, a homemade screening medium containing
ertapenem, cloxacillin, and zinc, namely, the SUPERCARBA
medium, has an excellent sensitivity and specificity for
the detection of carbapenemase producers, including NDM
producers. The zinc supplementation and the low ertapenem
concentration allow the efficient detection of all NDM pro-
ducers regardless of their level of resistance to carbapenems
[101, 104]. Consequently, using the SUPERCARBA medium
and performing the Carba NP test on isolated colonies might
be proposed as the recommended strategy for screening of
carbapenemase producers [105].
In order to avoid the additional 24 h to 48 h before
the carriage status of the patient can be established using
those screening media an in-house quantitative real-time
PCR assay using the TaqMan chemistry has been developed
to detect the NDM-encoding genes directly from spiked
stool samples. The bacterial extraction from stool samples
was performed manually or adapted to a fully automated
extraction system. This assay was found to be 100% specific
and sensitive with detection limits reproducible below 1 ×
10
1 CFU/100mg of feces [95]. However, this technology
remains expensive and is thus considered to be a valuable tool
in the follow-up of an outbreak and cohorting of colonized
patients.
9. Conclusion
The rapid diffusion of NDM producers is of particular
concern since this now corresponds to a worldwide-located
outbreak. Additional knowledge in relation to the driven
forces behind the spread of those multidrug-resistant isolates
is now required, in order to better understand the dynamics
of the NDM producers.
Among the most important features of NDM producers,
one may retain that those NDM producers are not only
nosocomial enterobacterial pathogens, but also community-
acquired Enterobacteriaceae or other Gram-negative species,
such as A. baumannii. Such diffusion pattern of multidrug
resistance is unique for NDM producers and not observed
currently for none of the producers of other types of car-
bapenemases (OXA-48, KPC, IMP. . .).
The reservoir of those NDM producers is mainly located
in Southeast Asia where the rate of carriers is estimated to
be ca. 20%. However, it is difficult to predict the number of
tourists in India, Pakistan, and Bangladesh (more than 10
million in 2012) that will bring back those NDM producers
at a carrier stage in stools. The size of that reservoir may
explain the rapidity of the dissemination of NDM producers
worldwide. Accordingly, NDM producers are now on the top
list of carbapenemase producers in European countries such
as the UK and even in France.
Due to the population demography of the NDM reser-
voirs coupled with the difficulties to implement hygiene
measures or an efficient antibiotic stewardship program in
those countries, the outbreak will not stop spontaneously.
On the opposite, we will see an acceleration of the NDM
producers spread worldwide. Hopefully the rate of NDM
producers will not reach those currently observed for ESBL
producers (20–80% worldwide).The spread of ESBL produc-
ers is an important driving force for usage of carbapenems
that will enhance selection of carbapenemase producers. The
only significant action we may actually take currently in
Western countries which are not endemic for carbapenemase
producers is to sustain the wide usage of rapid detection
techniques now available and the extended screening of
potential carriers at least in hospitals.
It is likely that novel antibiotic molecules such as the
combination of aztreonam and avibactam may be launched
in a near future and may bring some therapeutical open-
ings. However there is an urgent need to finance novel
research programs for discovering novel anti-Gram negatives
molecules and to implement worldwide-located surveillance
network of multidrug antibiotic resistance with sentinel labs.
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